pmid,title,mention_index,percent,percent_str,n,fraction_num,fraction_den,ci_level,ci_low,ci_high,context_snippet
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",0,95.0,95,,,,95.0,91.0,96.5,"thoDetect™ showed a sensitivity of 98.1 per cent [95% confidence interval (CI): 96.1-99.2], specificity"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",1,95.0,95,,,,95.0,91.0,96.5,"l (CI): 96.1-99.2], specificity of 94.2 per cent (95% CI: 91-96.5), PPV of 94.9 per cent (95% CI: 92.2-"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",2,95.0,95,,,,95.0,91.0,96.5,"per cent (95% CI: 91-96.5), PPV of 94.9 per cent (95% CI: 92.2-96.9), and NPV of 97.8 per cent (95% CI:"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",3,95.0,95,,,,95.0,91.0,96.5,"nt (95% CI: 92.2-96.9), and NPV of 97.8 per cent (95% CI: 95.5-99.1) with near-perfect agreement with T"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",4,95.0,95,,,,95.0,80.2,91.5,"F resistance with a sensitivity of 86.5 per cent (95% CI: 80.2-91.5), specificity of 91.6 per cent (95%"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",5,95.0,95,,,,95.0,80.2,91.5,"95% CI: 80.2-91.5), specificity of 91.6 per cent (95% CI: 88.2-94.3), PPV of 82.3 per cent (95% CI: 75."
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",6,95.0,95,,,,95.0,80.2,91.5,"r cent (95% CI: 88.2-94.3), PPV of 82.3 per cent (95% CI: 75.6-87.8), and NPV of 93.8 per cent (95% CI:"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",7,95.0,95,,,,95.0,88.2,94.3,"nt (95% CI: 75.6-87.8), and NPV of 93.8 per cent (95% CI: 90.7-96.1). For INH resistance, sensitivity w"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",8,95.0,95,,,,95.0,75.6,87.8,"or INH resistance, sensitivity was 88.9 per cent (95% CI: 84.1-92.6), specificity 87 per cent (95% CI:"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",9,95.0,95,,,,95.0,90.7,96.1,"ent (95% CI: 84.1-92.6), specificity 87 per cent (95% CI: 82.4-90.8), PPV 85.6 per cent (95% CI: 80.5-8"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",10,95.0,95,,,,95.0,84.1,92.6,"per cent (95% CI: 82.4-90.8), PPV 85.6 per cent (95% CI: 80.5-89.8), and NPV 90 per cent (95% CI: 85.7"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",11,95.0,95,,,,95.0,82.4,90.8,"er cent (95% CI: 80.5-89.8), and NPV 90 per cent (95% CI: 85.7-93.4) using pDST as reference. Truenat®"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",12,88.8,88.8,,,,,,,"Detect™ demonstrated higher sensitivity (93.4 vs. 88.8%), specificity (98.2 vs. 93.9%), PPV (96.1 vs. 86."
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",13,93.9,93.9,,,,,,,"nsitivity (93.4 vs. 88.8%), specificity (98.2 vs. 93.9%), PPV (96.1 vs. 86.8%) and NPV (97 vs. 94.9%) for"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",14,86.8,86.8,,,,,,,".8%), specificity (98.2 vs. 93.9%), PPV (96.1 vs. 86.8%) and NPV (97 vs. 94.9%) for RIF resistance detect"
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",15,94.9,94.9,,,,,,,"vs. 93.9%), PPV (96.1 vs. 86.8%) and NPV (97 vs. 94.9%) for RIF resistance detection over Truenat®. Inte"
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",0,12.0,12,,,,,,,"tion variables, with a non-inferiority margin of -12%. This trial is registered with ClinicalTrials.gov"
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",1,31.0,31,,,,,,,"28, 2023, 1030 individuals were screened and 324 (31%) were randomly assigned (219 to the BDLC group an"
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",2,46.0,46,,,,,,,he BDLC group and 105 to the control group). 114 (46%) participants were female and 133 (54%) were male
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",3,54.0,54,,,,,,,oup). 114 (46%) participants were female and 133 (54%) were male. Median age was 30·5 years (IQR 21·6-4
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",4,64.0,64,,,,,,,. Median age was 30·5 years (IQR 21·6-43·0). 157 (64%) participants had extensive disease at baseline.
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",5,29.0,29,,,,,,,"nsive disease at baseline. In the BDLC group, 47 (29%) of 163 were assigned to receive the 6-month regi"
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",6,71.0,71,,,,,,,assigned to receive the 6-month regimen and 116 (71%) the 9-month regimen. The core regimen of BDLC pl
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",7,91.0,91,,,,,,,DLC plus one or more other drugs was used for 76 (91%) of 84 participants in the control group. At week
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",8,87.0,87,,,,,,,"t week 73, favourable outcome was reached by 141 (87%) participants in the BDLC group versus 75 (89%) i"
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",9,89.0,89,,,,,,,1 (87%) participants in the BDLC group versus 75 (89%) in the control group in the mITT population (adj
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",10,2.0,2,,,,,,,n the mITT population (adjusted risk difference 0·2% [95% CI -9·1 to 9·5]; p The shortened BDLC strate
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",11,95.0,95,,,,,,,e mITT population (adjusted risk difference 0·2% [95% CI -9·1 to 9·5]; p The shortened BDLC strategy wa
40672039,Prognostic Value of Time-to-Positivity and Cycle Threshold (CT) Values in Predicting Tuberculosis Outcomes and Multidrug Resistance in Northern India: A Study Using Liquid Culture and Molecular Diagnostics.,0,52.8,52.8,,38.0,72.0,,,,biological outcomes. MGIT culture was positive in 52.8% (38/72) of patients (mean TTP: 26.5 days). In com
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",0,6.7,6.7,,,,,,,"and sub-lineage of lineage 1, 2, 3 and 4 were 13 (6.7 %), 63 (32.4 %), 82 (42.2 %) and 28 (14.4 %) respec"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",1,32.4,32.4,,,,,,,"age of lineage 1, 2, 3 and 4 were 13 (6.7 %), 63 (32.4 %), 82 (42.2 %) and 28 (14.4 %) respectively. Out o"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",2,42.2,42.2,,,,,,,"e 1, 2, 3 and 4 were 13 (6.7 %), 63 (32.4 %), 82 (42.2 %) and 28 (14.4 %) respectively. Out of total 194 c"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",3,14.4,14.4,,,,,,,"were 13 (6.7 %), 63 (32.4 %), 82 (42.2 %) and 28 (14.4 %) respectively. Out of total 194 culture isolates"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",4,81.5,81.5,,,,,,,"d in either single or in combinations: rpoB (146, 81.5 %), katG (138, 77 %), pncA (62, 34.6), gyrA (121, 6"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",5,77.0,77,,,,,,,"r in combinations: rpoB (146, 81.5 %), katG (138, 77 %), pncA (62, 34.6), gyrA (121, 67.5 %), embB (106,"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",6,67.5,67.5,,,,,,,"%), katG (138, 77 %), pncA (62, 34.6), gyrA (121, 67.5 %), embB (106, 59.2 %), rpsL (86,48 %) followed by"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",7,59.2,59.2,,,,,,,", pncA (62, 34.6), gyrA (121, 67.5 %), embB (106, 59.2 %), rpsL (86,48 %) followed by fabG1 (31, 17.3 %),"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",8,48.0,48,,,,,,,"gyrA (121, 67.5 %), embB (106, 59.2 %), rpsL (86,48 %) followed by fabG1 (31, 17.3 %), embA (18,10 %),"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",9,17.3,17.3,,,,,,,"6, 59.2 %), rpsL (86,48 %) followed by fabG1 (31, 17.3 %), embA (18,10 %), gid (6,3.3 %), inhA (4), eis (4"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",10,10.0,10,,,,,,,"86,48 %) followed by fabG1 (31, 17.3 %), embA (18,10 %), gid (6,3.3 %), inhA (4), eis (4,2.2 %), rrs (17"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",11,3.3,3.3,,,,,,,"wed by fabG1 (31, 17.3 %), embA (18,10 %), gid (6,3.3 %), inhA (4), eis (4,2.2 %), rrs (17, 9.4 %). Linea"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",12,2.2,2.2,,,,,,,", embA (18,10 %), gid (6,3.3 %), inhA (4), eis (4,2.2 %), rrs (17, 9.4 %). Lineage 2 was found to be most"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",13,9.4,9.4,,,,,,,"gid (6,3.3 %), inhA (4), eis (4,2.2 %), rrs (17, 9.4 %). Lineage 2 was found to be most mutated MTB stra"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",14,92.0,92,,,,,,,"oB, katG, gyrA, embB, and pncA gene mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respectively"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",15,82.5,82.5,,,,,,,"tG, gyrA, embB, and pncA gene mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respectively. This w"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",16,93.6,93.6,,,,,,,", embB, and pncA gene mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respectively. This was highe"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",17,68.2,68.2,,,,,,,"and pncA gene mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respectively. This was higher than i"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",18,61.9,61.9,,,,,,,"e mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respectively. This was higher than in lineage 1"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",19,30.7,30.7,,,,,,,"respectively. This was higher than in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), linea"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",20,53.8,53.8,,,,,,,"ively. This was higher than in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), lineage 3 (69"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",21,15.2,15.2,,,,,,,"his was higher than in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), lineage 3 (69.5 %, 68"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",22,38.4,38.4,,,,,,,"higher than in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), lineage 3 (69.5 %, 68.2 %, 46"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",23,0.0,0,,,,,,,"han in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), lineage 3 (69.5 %, 68.2 %, 46.3 %,"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",24,69.5,69.5,,,,,,,"%, 15.2 %, 38.4 %, 0 % respectively), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), an"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",25,68.2,68.2,,,,,,,"%, 38.4 %, 0 % respectively), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), and Euro-A"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",26,46.3,46.3,,,,,,,"%, 0 % respectively), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), and Euro-American"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",27,46.3,46.3,,,,,,,"respectively), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), and Euro-American lineage"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",28,24.3,24.3,,,,,,,"vely), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), and Euro-American lineage 4 (74 %,"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",29,74.0,74,,,,,,,"4.3 % respectively), and Euro-American lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). Ba"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",30,62.9,62.9,,,,,,,"respectively), and Euro-American lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). Based on t"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",31,48.1,48.1,,,,,,,"vely), and Euro-American lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). Based on this stud"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",32,40.7,40.7,,,,,,,"nd Euro-American lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). Based on this study, linea"
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",33,26.9,26.9,,,,,,,"American lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). Based on this study, lineage 3 may"
40540654,Diagnostic Modalities for Detecting Extrapulmonary Tuberculosis and Resistance Patterns of Rifampicin and Isoniazid at a Referral Hospital: A Retro Prospective Study.,0,11.9,11.9,,,,,,,"t® MTB/RIF detected M. tuberculosis in 339 cases (11.9%), significantly outperforming microscopy (183 cas"
40540654,Diagnostic Modalities for Detecting Extrapulmonary Tuberculosis and Resistance Patterns of Rifampicin and Isoniazid at a Referral Hospital: A Retro Prospective Study.,1,6.4,6.4,,,,,,,"ignificantly outperforming microscopy (183 cases, 6.4%). The highest positivity rates occurred in tissue"
40540654,Diagnostic Modalities for Detecting Extrapulmonary Tuberculosis and Resistance Patterns of Rifampicin and Isoniazid at a Referral Hospital: A Retro Prospective Study.,2,29.0,29,,,,,,,"rred in tissue biopsies and lymph node aspirates (29%), while genitourinary TB was least frequent. Rifa"
40540654,Diagnostic Modalities for Detecting Extrapulmonary Tuberculosis and Resistance Patterns of Rifampicin and Isoniazid at a Referral Hospital: A Retro Prospective Study.,3,4.13,4.13,,,,,,,"Rifampicin resistance was identified in 14 cases (4.13%), all confirmed as multidrug-resistant TB (MDR-TB"
40540654,Diagnostic Modalities for Detecting Extrapulmonary Tuberculosis and Resistance Patterns of Rifampicin and Isoniazid at a Referral Hospital: A Retro Prospective Study.,4,4.13,4.13,,,,,,,ow-resource settings. The high MDR-TB prevalence (4.13%) underscores the need for rapid molecular diagnos
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,0,47.5,47.50,,,,,,,"lagavi District, Karnataka. India. Most patients (47.50%) were aged 25-44 years. Of the 120 MDR-TB patient"
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,1,67.5,67.50,,,,,,,"ere aged 25-44 years. Of the 120 MDR-TB patients, 67.50% are male and 32.5% are female. Of 120 MDR-TB pati"
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,2,32.5,32.5,,,,,,,". Of the 120 MDR-TB patients, 67.50% are male and 32.5% are female. Of 120 MDR-TB patients, 7.50% are HIV"
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,3,7.5,7.50,,,,,,,"ale and 32.5% are female. Of 120 MDR-TB patients, 7.50% are HIV positive. As part of the study, smoking ("
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,4,26.67,26.67,,,,,,,"are HIV positive. As part of the study, smoking (26.67%), chewing tobacco (50%), and alcohol consumption"
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,5,50.0,50,,,,,,,"of the study, smoking (26.67%), chewing tobacco (50%), and alcohol consumption (33.33%) were found to"
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,6,33.33,33.33,,,,,,,", chewing tobacco (50%), and alcohol consumption (33.33%) were found to be other major risk factors. 24.17"
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,7,24.17,24.17,,,,,,,"3.33%) were found to be other major risk factors. 24.17% of patients had a family history of tuberculosis,"
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,8,5.0,5,,,,,,,"ts had a family history of tuberculosis, of which 5% had contact with an infected person as a source o"
40354869,Characterisation of M. tuberculosis isolates obtained from Tamil Nadu prevalence survey by whole genome sequencing analysis.,0,57.2,57.2,,,,,,,"le for further characterisation, out of which 71 (57.2 %) and 47 (37.9 %) were subjected to sequencing and"
40354869,Characterisation of M. tuberculosis isolates obtained from Tamil Nadu prevalence survey by whole genome sequencing analysis.,1,37.9,37.9,,,,,,,"haracterisation, out of which 71 (57.2 %) and 47 (37.9 %) were subjected to sequencing and phenotypic DST,"
40354869,Characterisation of M. tuberculosis isolates obtained from Tamil Nadu prevalence survey by whole genome sequencing analysis.,2,85.9,85.9,,,,,,,"isolates, sequencing data were available for 61 (85.9 %), where the lineage distribution and drug resista"
40354869,Characterisation of M. tuberculosis isolates obtained from Tamil Nadu prevalence survey by whole genome sequencing analysis.,3,90.0,90,,,,,,,nce between pDST and gDST for the drugs was above 90 % except for ETH (77 %) and INH (87 %). The phyloge
40354869,Characterisation of M. tuberculosis isolates obtained from Tamil Nadu prevalence survey by whole genome sequencing analysis.,4,77.0,77,,,,,,,gDST for the drugs was above 90 % except for ETH (77 %) and INH (87 %). The phylogenetic analysis of the
40354869,Characterisation of M. tuberculosis isolates obtained from Tamil Nadu prevalence survey by whole genome sequencing analysis.,5,87.0,87,,,,,,,ugs was above 90 % except for ETH (77 %) and INH (87 %). The phylogenetic analysis of the lineage distri
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,0,36.0,36,,,,,,,"ed patients from December 2020-December 2022, 42 (36%) exhibited a BDQ-resistant strain. Median (IQR) a"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,1,54.0,54,,,,,,,". Median (IQR) age was 24 (22-32) years, with 63 (54%) females and 94% with pulmonary TB. Patients with"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,2,94.0,94,,,,,,,"e was 24 (22-32) years, with 63 (54%) females and 94% with pulmonary TB. Patients with a BDQ-resistant"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,3,95.0,95,,,,,,,"kely to have lung cavities (risk ratio [RR]: 1.8; 95%-CI: 1.1-3.1; P = .02), and be resistant to clofaz"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,4,95.0,95,,,,,,,"= .02), and be resistant to clofazimine (RR: 2.3; 95%-CI: 1.5-3.6; P = .001). Overall, 102 patients ini"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,5,95.0,95,,33.0,38.0,,,,"s compared with BDQ-susceptible patients (RR:2.1; 95%-CI: 1.5-2.8; P < .001). Overall, 87% (33/38) of p"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,6,87.0,87,,33.0,38.0,,,,"nts (RR:2.1; 95%-CI: 1.5-2.8; P < .001). Overall, 87% (33/38) of patients with BDQ-resistance experienc"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,7,40.0,40,,33.0,38.0,,,,"e experienced unfavorable treatment outcomes: 15 (40%) died, 15 (40%) had treatment failure, and 3 (8%)"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,8,40.0,40,,33.0,38.0,,,,"nfavorable treatment outcomes: 15 (40%) died, 15 (40%) had treatment failure, and 3 (8%) were lost-to-f"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,9,8.0,8,,,,,,,"40%) died, 15 (40%) had treatment failure, and 3 (8%) were lost-to-follow-up. The study highlights a c"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,0,28.62,28.62,,,,,,,"ally, 255 MDR/RR-TB patients were analyzed and 73(28.62%) patients exhibited second-line drug (SLD) resist"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,1,89.04,89.04,,,,,,,"d-line drug (SLD) resistance. Among the cases, 65(89.04%) were found to be resistant solely to fluoroquino"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,2,4.11,4.11,,,,,,,"istant solely to fluoroquinolones (FQ), whereas 3(4.11%) were resistant only to aminoglycosides (pre-XDR"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,3,6.8,6.8,,,,,,,"only to aminoglycosides (pre-XDR TB). However, 5(6.8%) patients were resistant to both FQ and aminoglyc"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,4,60.37,60.37,,,,,,,oglycosides (XDR-TB). We also found that males 44(60.37%) were more affected by SLD resistance than 29(39.
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,5,39.72,39.72,,,,,,,"37%) were more affected by SLD resistance than 29(39.72%) females, however SLD resistant females were youn"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,6,71.23,71.23,,,,,,,"the gyrA gene was D94G, which was observed in 52(71.23%) cases, followed by A90V in 10(13.69%), D94N and"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,7,13.69,13.69,,,,,,,"erved in 52(71.23%) cases, followed by A90V in 10(13.69%), D94N and D94A in 4(5.48%), whereas the rrs gene"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,8,5.48,5.48,,,,,,,"ollowed by A90V in 10(13.69%), D94N and D94A in 4(5.48%), whereas the rrs gene presented the rrsMUT1 (A14"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,9,9.58,9.58,,,,,,,gene presented the rrsMUT1 (A1401G) mutation in 7(9.58%) and the rrsMUT2(G1484T) mutation in 1(1.37%) of
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,10,1.37,1.37,,,,,,,in 7(9.58%) and the rrsMUT2(G1484T) mutation in 1(1.37%) of SLD-resistant patients. The alarming rate of
40013634,Newer research transforming 24-month treatment of MDR/XDR-TB TO 6 months.,0,80.0,80,,,,,,,e year 2030; the aim is to reduce TB incidence by 80% and TB deaths by 90%. To eliminate the catastroph
40013634,Newer research transforming 24-month treatment of MDR/XDR-TB TO 6 months.,1,90.0,90,,,,,,,"is to reduce TB incidence by 80% and TB deaths by 90%. To eliminate the catastrophic cost, the Prime Mi"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",0,27.0,27,,,,,,,"of mortality globally, with India accounting for 27% of the estimated number of people with TB. Multid"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",1,7.0,7,,117.0,217.0,,,,"th drug-resistant TB initiated on treatment, 217 (7 %) had INH mono-resistant TB. Of these, 54 % (117/2"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",2,54.0,54,,117.0,217.0,,,,"t, 217 (7 %) had INH mono-resistant TB. Of these, 54 % (117/217) were female, with a median age of 26 ye"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",3,88.0,88,,191.0,217.0,,,,"years (interquartile range: 20-40). The majority (88 %; 191/217) presented with pulmonary TB, and most ("
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",4,87.0,87,,188.0,217.0,,,,"; 191/217) presented with pulmonary TB, and most (87 %; 188/217) had favourable treatment outcomes, incl"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",5,52.0,52,,112.0,217.0,,,,"eatment outcomes, including treatment completion (52 %; 112/217) and cure (35 %; 76/217). Unfavourable o"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",6,35.0,35,,76.0,217.0,,,,"ng treatment completion (52 %; 112/217) and cure (35 %; 76/217). Unfavourable outcomes, including treatm"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",7,2.3,2.3,,5.0,217.0,,,,"favourable outcomes, including treatment failure (2.3 %; 5/217), loss to follow-up (9.2 %; 20/217), or de"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",8,9.2,9.2,,20.0,217.0,,,,"atment failure (2.3 %; 5/217), loss to follow-up (9.2 %; 20/217), or death (1.8 %; 4/217), were observed"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",9,1.8,1.8,,4.0,217.0,,,,"17), loss to follow-up (9.2 %; 20/217), or death (1.8 %; 4/217), were observed in 13 % (29/217) of patien"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",10,13.0,13,,29.0,217.0,,,,"0/217), or death (1.8 %; 4/217), were observed in 13 % (29/217) of patients. A total of ten (5 %) patien"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",11,5.0,5,,29.0,217.0,,,,ved in 13 % (29/217) of patients. A total of ten (5 %) patients experienced at least one non-severe adv
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,0,100.0,100,,,,,,,icroscopy centres of both selected districts i.e. 100% sample size are covered in the study. Hand washin
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,1,66.66,66.66,,,,,,,on and control of infection. In Dehradun district 66.66% (12) centers and in Ghaziabad district 57.14% (16
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,2,57.14,57.14,,,,,,,ict 66.66% (12) centers and in Ghaziabad district 57.14% (16) centers have adequate hand washing facility
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,3,55.56,55.56,,,,,,,"will lead to the infection. In Dehradun district, 55.56% (10) centers have adequate PPE available whereas"
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,4,21.43,21.43,,,,,,,quate PPE available whereas in Ghaziabad District 21.43% (6) centers have adequate PPE available. Training
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,5,27.78,27.78,,,,,,,n prevention and control for HCWs are provided in 27.78% (5) DOTS/sputum microscopy center in Dehradun whe
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,6,33.33,33.33,,,,,,,no proper ventilation in their working places. In 33.33% (6) DOTS/sputum microscopy center in Dehradun & 2
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,7,28.57,28.57,,,,,,,% (6) DOTS/sputum microscopy center in Dehradun & 28.57% (8) in Ghaziabad district have adequate ventilati
39277889,Diagnostics Evaluation of Smart Sure™ Mycobacterium tuberculosis Screening Kit and Smart Sure™ Multidrug-resistant Tuberculosis Detection Kit on Nonsputum Specimens at a Tertiary Care Center of North India.,0,71.59,71.59,,,,,,,"specificity of Smart Sure™ MTB screening kit was 71.59% and 98.28%, respectively, with Xpert ultra and 68"
39277889,Diagnostics Evaluation of Smart Sure™ Mycobacterium tuberculosis Screening Kit and Smart Sure™ Multidrug-resistant Tuberculosis Detection Kit on Nonsputum Specimens at a Tertiary Care Center of North India.,1,98.28,98.28,,,,,,,"y of Smart Sure™ MTB screening kit was 71.59% and 98.28%, respectively, with Xpert ultra and 68.35% and 90"
39277889,Diagnostics Evaluation of Smart Sure™ Mycobacterium tuberculosis Screening Kit and Smart Sure™ Multidrug-resistant Tuberculosis Detection Kit on Nonsputum Specimens at a Tertiary Care Center of North India.,2,68.35,68.35,,,,,,,"9% and 98.28%, respectively, with Xpert ultra and 68.35% and 90.83%, respectively, with MGIT culture. Whil"
39277889,Diagnostics Evaluation of Smart Sure™ Mycobacterium tuberculosis Screening Kit and Smart Sure™ Multidrug-resistant Tuberculosis Detection Kit on Nonsputum Specimens at a Tertiary Care Center of North India.,3,90.83,90.83,,,,,,,"8%, respectively, with Xpert ultra and 68.35% and 90.83%, respectively, with MGIT culture. While comparing"
39277889,Diagnostics Evaluation of Smart Sure™ Mycobacterium tuberculosis Screening Kit and Smart Sure™ Multidrug-resistant Tuberculosis Detection Kit on Nonsputum Specimens at a Tertiary Care Center of North India.,4,75.0,75.0,,,,,,,"nt, Smart Sure™ MDR-TB kits showed sensitivity of 75.0% and 100% of specificity. However, for isoniazid ("
39277889,Diagnostics Evaluation of Smart Sure™ Mycobacterium tuberculosis Screening Kit and Smart Sure™ Multidrug-resistant Tuberculosis Detection Kit on Nonsputum Specimens at a Tertiary Care Center of North India.,5,100.0,100,,,,,,,"Sure™ MDR-TB kits showed sensitivity of 75.0% and 100% of specificity. However, for isoniazid (INH) resi"
39277889,Diagnostics Evaluation of Smart Sure™ Mycobacterium tuberculosis Screening Kit and Smart Sure™ Multidrug-resistant Tuberculosis Detection Kit on Nonsputum Specimens at a Tertiary Care Center of North India.,6,100.0,100,,,,,,,"(INH) resistance, Smart Sure™ MDR-TB kits showed 100% of sensitivity and specificity with MGIT-DST. For"
39067958,"Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India.",0,52.9,52.9,,,,,,,"etrospectively. Out of 155 patients enrolled, 82 (52.9 %) were cured, 31 (20 %) completed treatment, 18 (1"
39067958,"Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India.",1,20.0,20,,,,,,,"55 patients enrolled, 82 (52.9 %) were cured, 31 (20 %) completed treatment, 18 (11.6 %) defaulted, 22 ("
39067958,"Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India.",2,11.6,11.6,,,,,,,"%) were cured, 31 (20 %) completed treatment, 18 (11.6 %) defaulted, 22 (14.2 %) died and 2 (0.12 %) faile"
39067958,"Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India.",3,14.2,14.2,,,,,,,") completed treatment, 18 (11.6 %) defaulted, 22 (14.2 %) died and 2 (0.12 %) failed treatment. Bdq is wel"
39067958,"Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India.",4,0.12,0.12,,,,,,,"t, 18 (11.6 %) defaulted, 22 (14.2 %) died and 2 (0.12 %) failed treatment. Bdq is well tolerated with ver"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,0,42.45,42.45,,,,,,,"f 110 individuals with the disease. Of these, 45 (42.45%) experienced linezolid ADRs, with an incidence of"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,1,50.0,50,,,,,,,"± 11.13 years) and more likely to be female (27, 50%) than those without ADRs. ADR severity was mild i"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,2,44.45,44.45,,,,,,,"those without ADRs. ADR severity was mild in 20 (44.45%), moderate in 15 (33.33%), and severe in 10 (22.2"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,3,33.33,33.33,,,,,,,"severity was mild in 20 (44.45%), moderate in 15 (33.33%), and severe in 10 (22.22%) patients. The most co"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,4,22.22,22.22,,,,,,,".45%), moderate in 15 (33.33%), and severe in 10 (22.22%) patients. The most common ADR was peripheral neu"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,5,93.33,93.33,,,,,,,"he most common ADR was peripheral neuropathy (42, 93.33%), followed by lactic acidosis (3, 6.67%), anemia"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,6,6.67,6.67,,,,,,,"thy (42, 93.33%), followed by lactic acidosis (3, 6.67%), anemia (2, 4.44%), and optic neuritis (2, 4.44%"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,7,4.44,4.44,,,,,,,"ollowed by lactic acidosis (3, 6.67%), anemia (2, 4.44%), and optic neuritis (2, 4.44%). Dosing was reduc"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,8,4.44,4.44,,,,,,,"6.67%), anemia (2, 4.44%), and optic neuritis (2, 4.44%). Dosing was reduced in 17 (37.78%) patients, and"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,9,37.78,37.78,,,,,,,"ic neuritis (2, 4.44%). Dosing was reduced in 17 (37.78%) patients, and linezolid was withdrawn entirely i"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,10,42.22,42.22,,,,,,,"ents, and linezolid was withdrawn entirely in 19 (42.22%) patients. Only 9 (20%) patients continued linezo"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,11,20.0,20,,,,,,,thdrawn entirely in 19 (42.22%) patients. Only 9 (20%) patients continued linezolid unmodified. For mil
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,12,6.67,6.67,,,,,,,".33 weeks, ADR symptoms resolved completely in 4 (6.67%) patients and decreased in 42 (93.33%) patients."
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,13,93.33,93.33,,,,,,,"letely in 4 (6.67%) patients and decreased in 42 (93.33%) patients. Linezolid ADRs, often neuropathy, freq"
37968050,Comparison of gastric lavage/sputum and stool specimens in the diagnosis of pediatric pulmonary tuberculosis- A pilot study.,0,11.0,11,,,,,,,"Global TB report 2021 mentions 11 % prevalence of pediatric TB, whereas 5.65% of the"
37968050,Comparison of gastric lavage/sputum and stool specimens in the diagnosis of pediatric pulmonary tuberculosis- A pilot study.,1,5.65,5.65,,,,,,,"mentions 11 % prevalence of pediatric TB, whereas 5.65% of the cases were reported from India in 2020. In"
37968050,Comparison of gastric lavage/sputum and stool specimens in the diagnosis of pediatric pulmonary tuberculosis- A pilot study.,2,26.0,26,,,,,,,"fampicin resistance was detected in 13 of the 50 (26%) GL/SP specimens. Of these 13 children, rifampici"
37919487,Current Epidemiology of Pediatric Tuberculosis.,0,31.0,31,,,,,,,"em with TB in children, which accounts for around 31% of the global pediatric TB load. However, over th"
37919487,Current Epidemiology of Pediatric Tuberculosis.,1,7.0,7,,,,,,,"e past 10 y, children have consistently made up 6-7% of all patients treated yearly under the National"
37919487,Current Epidemiology of Pediatric Tuberculosis.,2,56.0,56,,,,,,,"me (NTEP). There is an estimated detection gap of 56% in India, which is the reason for many missed cas"
37919487,Current Epidemiology of Pediatric Tuberculosis.,3,3.0,3,,,,,,,"son for many missed cases of TB in children. Only 3% of children less than 14 y with MDR/RR-TB, are re"
37724763,The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.,0,70.0,70,,,,,,,"an MDR/RR-TPT regimen (assuming 6-month duration, 70% efficacy) and associated active case finding agai"
37724763,The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.,1,72.0,72,,,,,,,"typical trial, MDR/RR-TPT was measured to prevent 72% (interquartile range, 45%-100%) of incident MDR/R"
37724763,The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.,2,45.0,45,,,,,,,"was measured to prevent 72% (interquartile range, 45%-100%) of incident MDR/RR-TB among recipients; the"
37724763,The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.,3,100.0,100,,,,,,,"measured to prevent 72% (interquartile range, 45%-100%) of incident MDR/RR-TB among recipients; the medi"
37636185,Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic.,0,85.0,85,,,,,,,"5 MDR/RR-TB cases were detected in India, 56,569 (85%) were put on treatment, and 40,397 (75%) were ini"
37636185,Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic.,1,75.0,75,,,,,,,", 56,569 (85%) were put on treatment, and 40,397 (75%) were initiated on shorter drug regimens at the t"
37636185,Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic.,2,65.2,65.2,,,,,,,"ded. The success rate using a shorter regimen was 65.2% which is respectable, given the COVID-19 pandemic"
37636185,Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic.,3,39.3,39.3,,,,,,,tudy period. Minor adverse events such as nausea (39.3%) and vomiting (34.8%) were reported. Rare adverse
37636185,Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic.,4,34.8,34.8,,,,,,,verse events such as nausea (39.3%) and vomiting (34.8%) were reported. Rare adverse effects such as hear
37636185,Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic.,5,8.9,8.9,,,,,,,orted. Rare adverse effects such as hearing loss (8.9%) and hypothyroidism (0.2%) were also seen in the
37636185,Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic.,6,0.2,0.2,,,,,,,s such as hearing loss (8.9%) and hypothyroidism (0.2%) were also seen in the study population. Overall
37406039,Maternal Colonization Versus Nosocomial Transmission as the Source of Drug-Resistant Bloodstream Infection in an Indian Neonatal Intensive Care Unit: A Prospective Cohort Study.,0,9.3,9.3,21.0,,,,,,"ed, 257 neonates required NICU admission, and 24 (9.3%) developed BSI. Among mothers of neonates with GN"
37406039,Maternal Colonization Versus Nosocomial Transmission as the Source of Drug-Resistant Bloodstream Infection in an Indian Neonatal Intensive Care Unit: A Prospective Cohort Study.,1,47.7,47.7,21.0,,,,,,"ong mothers of neonates with GN BSI (n = 21), 10 (47.7%) had rectal, 5 (23.8%) had vaginal, and 10 (47.7%"
37406039,Maternal Colonization Versus Nosocomial Transmission as the Source of Drug-Resistant Bloodstream Infection in an Indian Neonatal Intensive Care Unit: A Prospective Cohort Study.,2,23.8,23.8,21.0,,,,,,"s with GN BSI (n = 21), 10 (47.7%) had rectal, 5 (23.8%) had vaginal, and 10 (47.7%) had no colonization"
37406039,Maternal Colonization Versus Nosocomial Transmission as the Source of Drug-Resistant Bloodstream Infection in an Indian Neonatal Intensive Care Unit: A Prospective Cohort Study.,3,47.7,47.7,21.0,,,,,,"47.7%) had rectal, 5 (23.8%) had vaginal, and 10 (47.7%) had no colonization with resistant GN organisms."
37406039,Maternal Colonization Versus Nosocomial Transmission as the Source of Drug-Resistant Bloodstream Infection in an Indian Neonatal Intensive Care Unit: A Prospective Cohort Study.,4,57.0,57,,,,,,,". Among 37 of 51 BSI with available NGS data, 21 (57%) showed a single nucleotide polymorphism distance"
37234098,Studying the efficacy of isolation as a control strategy and elimination of tuberculosis in India: A mathematical model.,0,47.0,47,,,,,,,"2.2 million, which was 1.5 million in 2009. About 47% increment in TB case notification in India within"
37234098,Studying the efficacy of isolation as a control strategy and elimination of tuberculosis in India: A mathematical model.,1,22.0,22,,,,,,,nt public health problem. India contributes about 22% of the World's TB burden. Indian National Strateg
37234098,Studying the efficacy of isolation as a control strategy and elimination of tuberculosis in India: A mathematical model.,2,95.0,95,,,,,,,"f the treatment success rate could be achieved to 95%, by contact tracing and isolating at least 50% of"
37234098,Studying the efficacy of isolation as a control strategy and elimination of tuberculosis in India: A mathematical model.,3,50.0,50,,,,,,,"to 95%, by contact tracing and isolating at least 50% of MDR-TB."
36962909,"Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.",0,3.0,3,,,,,,,time horizon. Costs and DALYs were discounted at 3% in the base case. Parameter uncertainty was teste
36740313,Need to reinvigorateTuberculosis research in India - A review of studies registered under clinical trial registry of India.,0,0.58,0.58,,,,,,,"tudies were registered in CTRI, with 180 studies (0.58%) being related to tuberculosis. Of these studies,"
36740313,Need to reinvigorateTuberculosis research in India - A review of studies registered under clinical trial registry of India.,1,42.2,42.2,90.0,,,,,,"ng related to tuberculosis. Of these studies, 76 (42.2%) were interventional in nature. These consisted o"
36740313,Need to reinvigorateTuberculosis research in India - A review of studies registered under clinical trial registry of India.,2,50.0,50,90.0,,,,,,"evaluating different management or treatment TB (50%, n = 90), diagnostic studies (19.4%, n = 35) and"
36740313,Need to reinvigorateTuberculosis research in India - A review of studies registered under clinical trial registry of India.,3,19.4,19.4,35.0,,,,,,"r treatment TB (50%, n = 90), diagnostic studies (19.4%, n = 35) and studies related to screening and pre"
36740313,Need to reinvigorateTuberculosis research in India - A review of studies registered under clinical trial registry of India.,4,7.8,7.8,14.0,,,,,,"tudies related to screening and prevention of TB (7.8%, n = 14). Maximum studies were conducted to evalu"
36740313,Need to reinvigorateTuberculosis research in India - A review of studies registered under clinical trial registry of India.,5,10.0,10,18.0,,,,,,"to evaluate safety and efficacy of anti-TB drugs (10%, n = 18) and to evaluate efficacy of shortening o"
36740313,Need to reinvigorateTuberculosis research in India - A review of studies registered under clinical trial registry of India.,6,8.9,8.9,16.0,,,,,,"efficacy of shortening of duration of treatment (8.9%, n = 16). The studies related to extra pulmonary"
36272707,Whole-genome sequencing of presumptive MDR-TB isolates from a tertiary healthcare setting in Mumbai.,0,93.0,93,93.0,,,,,,"variants were observed in the rpoB gene (n = 93, 93%), wherein the Ser450Leu was the predominant mutat"
36272707,Whole-genome sequencing of presumptive MDR-TB isolates from a tertiary healthcare setting in Mumbai.,1,73.0,73,68.0,,,,,,"e Ser450Leu was the predominant mutation (n = 68, 73%). Ser315Thr was the most common variant (n = 86,"
36272707,Whole-genome sequencing of presumptive MDR-TB isolates from a tertiary healthcare setting in Mumbai.,2,97.0,97,86.0,,,,,,"). Ser315Thr was the most common variant (n = 86, 97%) that encoded resistance to isoniazid. The Lys43A"
36272707,Whole-genome sequencing of presumptive MDR-TB isolates from a tertiary healthcare setting in Mumbai.,3,89.0,89,65.0,,,,,,"d was the third most predominant variant (n = 65, 89%). In addition to the high levels of resistance ob"
36272707,Whole-genome sequencing of presumptive MDR-TB isolates from a tertiary healthcare setting in Mumbai.,4,63.0,63,63.0,,,,,,"ved a high proportion of Beijing strains (n = 63, 63%). Compared with results from routine diagnostics"
36200688,Factors affecting the treatment outcome of injection based shorter MDR-TB regimen at a referral centre in India.,0,50.91,50.91,,,,,,,"d not. A total of 55 patients were enrolled, with 50.91% being successful (cured/treatment completed) and"
36200688,Factors affecting the treatment outcome of injection based shorter MDR-TB regimen at a referral centre in India.,1,49.09,49.09,,,,,,,"being successful (cured/treatment completed) and 49.09% failing (including failure, lost to follow up, de"
35989319,High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.,0,36.0,36,,,,,,,of the global MDR tuberculosis (TB) burden. About 36% of the MDR MTBC strains are reported fluoroquinol
35989319,High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.,1,69.2,69.2,,,,,,,"al, 1016 MTBC strains were MDR, out of which 703 (69.2%) were pre-XDR and 45 (4.4%) were XDR. Cluster rat"
35989319,High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.,2,4.4,4.4,,,,,,,"DR, out of which 703 (69.2%) were pre-XDR and 45 (4.4%) were XDR. Cluster rates were high among MDR (57."
35989319,High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.,3,57.8,57.8,,,,,,,.4%) were XDR. Cluster rates were high among MDR (57.8%) and pre-XDR/XDR (79%) strains with three dominan
35989319,High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.,4,79.0,79,,,,,,,ates were high among MDR (57.8%) and pre-XDR/XDR (79%) strains with three dominant L2 (Beijing) strain
35989319,High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.,5,40.0,40,,,,,,,ers (Cl 1-3) representing half of the pre-XDR and 40% of the XDR-TB cases. L2 strains were associated w
35989319,High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.,6,90.6,90.6,,,,,,,had high first-line and FQ resistance rates (81.6-90.6%). Epidemic success analysis using THD showed that
35760485,"Health-related quality of life of multidrug-resistant tuberculosis patients: A study of eastern Uttar Pradesh, India.",0,45.85,45.85,,,,,,,otal of 157 patients were included in the study & 45.85% were dissatisfied with their condition. Social do
35435077,"Spoligotyping of Mycobacterium tuberculosis isolates from Pulmonary Tuberculosis patients from North Karnataka, India.",0,27.0,27,,,,,,,threat to control programmes. India accounts for 27% TB cases worldwide. Our study was undertaken to u
35044136,"Determinants, risk factors and spatial analysis of multi-drug resistant pulmonary tuberculosis in Jodhpur, India.",0,23.0,23,,,,,,,"ic acid amplification test) were performed. 2898 (23%) showed M. TB positive but rifampicin sensitive,"
35044136,"Determinants, risk factors and spatial analysis of multi-drug resistant pulmonary tuberculosis in Jodhpur, India.",1,4.7,4.7,,,,,,,"M. TB positive but rifampicin sensitive, and 590 (4.7%) showed rifampicin resistant. Independent risk fa"
34752317,Drug resistance pattern and mutation pattern in pediatric tuberculosis: Study from north India.,0,61.1,61.1,,,,,,,g resistance by Hain's GenoType MTBDRplus VER 2.0.61.1% were sensitive to isoniazid and rifampicin while
34752317,Drug resistance pattern and mutation pattern in pediatric tuberculosis: Study from north India.,1,15.2,15.2,,,,,,,"were sensitive to isoniazid and rifampicin while 15.2% were DR-TB (38 out of 250). Out of these 38, 22 w"
34752317,Drug resistance pattern and mutation pattern in pediatric tuberculosis: Study from north India.,2,34.2,34.2,,,,,,,"22 were MDR TB, 13 were isoniazid monoresistant (34.2%) and 3 were rifampicin monoresistant. The most co"
34752317,Drug resistance pattern and mutation pattern in pediatric tuberculosis: Study from north India.,3,88.0,88,,,,,,,of rpoB WT8 band and presence of rpoB MUT 3 band (88%). 84.6% of the INH monoresistant isolates showed
34752317,Drug resistance pattern and mutation pattern in pediatric tuberculosis: Study from north India.,4,84.6,84.6,,,,,,,B WT8 band and presence of rpoB MUT 3 band (88%). 84.6% of the INH monoresistant isolates showed high lev
34752313,Prevalence of depression and anxiety among drug resistant tuberculosis: A study in North India.,0,68.0,68,,,,,,,alence rate of depression in MDR-TB and XDR-TB is 68% and 78% respectively. The prevalence of anxiety i
34752313,Prevalence of depression and anxiety among drug resistant tuberculosis: A study in North India.,1,78.0,78,,,,,,,ate of depression in MDR-TB and XDR-TB is 68% and 78% respectively. The prevalence of anxiety is 54% in
34752313,Prevalence of depression and anxiety among drug resistant tuberculosis: A study in North India.,2,54.0,54,,,,,,,nd 78% respectively. The prevalence of anxiety is 54% in MDR-TB and 66% in XDR-TB respectively in our s
34752313,Prevalence of depression and anxiety among drug resistant tuberculosis: A study in North India.,3,66.0,66,,,,,,,y. The prevalence of anxiety is 54% in MDR-TB and 66% in XDR-TB respectively in our study. Duration of
34637049,Mycobacterium tuberculosis strain lineage in mixed tribal population across India and Andaman Nicobar Island.,0,8.6,8.6,,,,,,,"n India, the tribal population constitutes almost 8.6% of the nation's total population. Despite their l"
34637049,Mycobacterium tuberculosis strain lineage in mixed tribal population across India and Andaman Nicobar Island.,1,15.4,15.4,,,,,,,usceptibility testing (DST) results showed almost 15.4% of clinical isolates found to be resistant to iso
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",0,20.0,20,,,,,,,was used for GenoType MTBDRsl v.2.0 assay. While 20% of the decontaminated specimens were inoculated i
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",1,26.6,26.6,,,,,,,"e MTBDRsl v.2.0 assay. Of the 1178 MTBC positive, 26.6% were sensitive to both FQs and SLIDs, whereas 57."
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",2,57.3,57.3,,,,,,,".6% were sensitive to both FQs and SLIDs, whereas 57.3% were only FQs resistant and 15.9% were resistant"
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",3,15.9,15.9,,,,,,,"SLIDs, whereas 57.3% were only FQs resistant and 15.9% were resistant to both FQs and SLIDs. Further DST"
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",4,17.0,17,,,,,,,"DST of 225 isolates by liquid culture showed that 17% were sensitive to both FQs and SLIDs, 61.3% were"
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",5,61.3,61.3,,,,,,,"ed that 17% were sensitive to both FQs and SLIDs, 61.3% were only FQs resistant and 21.3% were resistant"
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",6,21.3,21.3,,,,,,,"FQs and SLIDs, 61.3% were only FQs resistant and 21.3% were resistant to both. The specificity for FQs a"
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",7,92.31,92.31,,,,,,,nt to both. The specificity for FQs and SLIDs was 92.31% and 100% whereas sensitivity was 100% respectivel
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",8,100.0,100,,,,,,,The specificity for FQs and SLIDs was 92.31% and 100% whereas sensitivity was 100% respectively by Geno
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",9,100.0,100,,,,,,,SLIDs was 92.31% and 100% whereas sensitivity was 100% respectively by GenoType MTBDRsl v.2.0 assay in d
34343039,Pattern of Drug Resistance in Primary Spinal Tuberculosis: A Single-Center Study From India.,0,50.0,50,,,,,,,analysis. Spinal tuberculosis accounts for about 50% of cases among extra pulmonary osteoarticular tub
34343039,Pattern of Drug Resistance in Primary Spinal Tuberculosis: A Single-Center Study From India.,1,24.0,24,,,,,,,f resistance in Indian subcontinent which harbors 24% of global prevalence. The aim was to study the pa
34343039,Pattern of Drug Resistance in Primary Spinal Tuberculosis: A Single-Center Study From India.,2,28.6,28.6,,,,,,,"resistance in spinal tuberculosis was found to be 28.6%. Of these, MDR was in 16.2%, pre-XDR in 20.9%, an"
34343039,Pattern of Drug Resistance in Primary Spinal Tuberculosis: A Single-Center Study From India.,3,16.2,16.2,,,,,,,"losis was found to be 28.6%. Of these, MDR was in 16.2%, pre-XDR in 20.9%, and XDR in 9.3% patients."
34343039,Pattern of Drug Resistance in Primary Spinal Tuberculosis: A Single-Center Study From India.,4,20.9,20.9,,,,,,,"be 28.6%. Of these, MDR was in 16.2%, pre-XDR in 20.9%, and XDR in 9.3% patients."
34343039,Pattern of Drug Resistance in Primary Spinal Tuberculosis: A Single-Center Study From India.,5,9.3,9.3,,,,,,,"e, MDR was in 16.2%, pre-XDR in 20.9%, and XDR in 9.3% patients."
33632218,The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.,0,50.0,50,,,,,,,"efficacy, conferring 10 years of protection, with 50% efficacy. We measured vaccine cost-effectiveness"
33632218,The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.,1,71.0,71,,,,,,,"P&PI vaccine reduced RR/MDR-TB incidence rate by 71% (UI: 69-72) and 72% (UI: 70-74), and the PSI vacc"
33632218,The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.,2,72.0,72,,,,,,,"d RR/MDR-TB incidence rate by 71% (UI: 69-72) and 72% (UI: 70-74), and the PSI vaccine by 31% (UI: 30-3"
33632218,The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.,3,31.0,31,,,,,,,"9-72) and 72% (UI: 70-74), and the PSI vaccine by 31% (UI: 30-32) and 44% (UI: 42-47) in China and Indi"
33632218,The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.,4,44.0,44,,,,,,,"0-74), and the PSI vaccine by 31% (UI: 30-32) and 44% (UI: 42-47) in China and India, respectively. In"
33632218,The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.,5,49.0,49,,,,,,,d cost-effective at the lower HCOC threshold with 49% probability and PSI vaccines at the upper HCOC th
33632218,The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.,6,21.0,21,,,,,,,and PSI vaccines at the upper HCOC threshold with 21% probability. The P&PI vaccine was predicted to av
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",0,6.0,6,,,,,,,2020. A total of 268 patients were included; 16 (6%) of them were children (0-9 years). The median(mi
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",1,72.0,72,,,,,,,"e median(min-max) age was 17(4-19) years and 192 (72%) were females. Majority (199, 74%) had pulmonary"
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",2,74.0,74,,,,,,,"years and 192 (72%) were females. Majority (199, 74%) had pulmonary TB. Most (58%) had MDR-TB while 42"
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",3,58.0,58,239.0,,,,,,"ales. Majority (199, 74%) had pulmonary TB. Most (58%) had MDR-TB while 42% had fluoroquinolone-resista"
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",4,42.0,42,239.0,,,,,,4%) had pulmonary TB. Most (58%) had MDR-TB while 42% had fluoroquinolone-resistant TB. The median(IQR)
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",5,62.0,62,128.0,,,,,,"(n = 128) was 3(3-4) months. Of 268 patients, 166(62%) had successful end-of-treatment outcomes (cured-"
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",6,94.0,94,,,,,,,gher proportion of successful treatment outcomes (94% versus 60%) compared to adolescents. Patients wit
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",7,60.0,60,,,,,,,tion of successful treatment outcomes (94% versus 60%) compared to adolescents. Patients with undernutr
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",8,95.0,95,,,,,,,"ts with undernutrition [adjusted odds-ratio, aOR (95% Confidence Interval, 95%CI): 2.5 (1.3-4.8) or tho"
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",9,95.0,95,,,,,,,"djusted odds-ratio, aOR (95% Confidence Interval, 95%CI): 2.5 (1.3-4.8) or those with XDR-TB [aOR (95%"
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",10,95.0,95,,,,,,,95%CI): 2.5 (1.3-4.8) or those with XDR-TB [aOR (95% CI): 4.3 (1.3-13.8)] had higher likelihood of hav
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",0,73.0,73,,,,,,,"nts with MDR-TB. Sixty-nine patients with MDR-TB (73%) reported ADRs. Tingling (42.6%), headache (37.2%"
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",1,42.6,42.6,,,,,,,"tients with MDR-TB (73%) reported ADRs. Tingling (42.6%), headache (37.2%), numbness (36.2%), dizziness ("
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",2,37.2,37.2,,,,,,,"(73%) reported ADRs. Tingling (42.6%), headache (37.2%), numbness (36.2%), dizziness (34%) and nausea (3"
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",3,36.2,36.2,,,,,,,"Rs. Tingling (42.6%), headache (37.2%), numbness (36.2%), dizziness (34%) and nausea (33%) were the most"
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",4,34.0,34,,,,,,,"), headache (37.2%), numbness (36.2%), dizziness (34%) and nausea (33%) were the most common ADRs. Of t"
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",5,33.0,33,,,,,,,"%), numbness (36.2%), dizziness (34%) and nausea (33%) were the most common ADRs. Of the 94 patients, 7"
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",6,7.4,7.4,,,,,,,"%) were the most common ADRs. Of the 94 patients, 7.4% were compelled to think of discontinuing their tr"
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",7,8.5,8.5,,,,,,,ink of discontinuing their treatment due to ADRs; 8.5% had discontinued Cat-I/Cat-II regimen in the past
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",8,11.7,11.7,,,,,,,ad discontinued Cat-I/Cat-II regimen in the past; 11.7% had discontinued their MDR-TB regimen in the past
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",9,13.8,13.8,,,,,,,ad discontinued their MDR-TB regimen in the past; 13.8% had their drug regimen changed due to ADRs and 94
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",10,94.7,94.7,,,,,,,8% had their drug regimen changed due to ADRs and 94.7% had good adherence to their current regimen (took
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",11,80.0,80,,,,,,,adherence to their current regimen (took at least 80% of their doses till date). ADRs were the reason f
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",12,75.0,75,,,,,,,their doses till date). ADRs were the reason for 75% of the patients who discontinued their Cat-I/Cat-
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",13,64.0,64,,,,,,,tinued their Cat-I/Cat-II regimen in the past and 64% of the patients who discontinued their MDR-TB reg
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,0,5.4,5.4,,,,,,,"nt and Isoniazid mono-resistant TB were found in 5.4%, 2.5%, and 11.4% cases of presumptive MDR-TB, res"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,1,2.5,2.5,,,,,,,"Isoniazid mono-resistant TB were found in 5.4%, 2.5%, and 11.4% cases of presumptive MDR-TB, respectiv"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,2,11.4,11.4,,,,,,,"mono-resistant TB were found in 5.4%, 2.5%, and 11.4% cases of presumptive MDR-TB, respectively. Based"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,3,38.0,38,,,,,,,"nd inferred resistance to Rifampicin was found in 38%, 29.3%, and 32.7% of the 1582 MDR cases, respecti"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,4,29.3,29.3,,,,,,,"ferred resistance to Rifampicin was found in 38%, 29.3%, and 32.7% of the 1582 MDR cases, respectively. S"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,5,32.7,32.7,,,,,,,"stance to Rifampicin was found in 38%, 29.3%, and 32.7% of the 1582 MDR cases, respectively. S450L (MUT3)"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,6,59.4,59.4,,,,,,,UT3) was the most common rpoB mutation present in 59.4% of the Rifampicin resistant cases. Of the 3390 Is
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,7,72.5,72.5,,,,,,,"ant cases. Of the 3390 Isoniazid resistant cases, 72.5% had mutations in the katG gene, and 27.5% had mut"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,8,27.5,27.5,,,,,,,"cases, 72.5% had mutations in the katG gene, and 27.5% had mutations in the inhA gene. True resistance,"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,9,42.9,42.9,,,,,,,"resistance, and inferred resistance accounted for 42.9%, 22.2%, and 17.3% of the 2459 katG resistant case"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,10,22.2,22.2,,,,,,,"nce, and inferred resistance accounted for 42.9%, 22.2%, and 17.3% of the 2459 katG resistant cases, resp"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,11,17.3,17.3,,,,,,,"ferred resistance accounted for 42.9%, 22.2%, and 17.3% of the 2459 katG resistant cases, respectively. T"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,12,54.5,54.5,,,,95.0,1.747,5.754,"ferred resistance for the inhA gene were found in 54.5%, 40.7%, and 4.7% cases, respectively. MDR-contact"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,13,40.7,40.7,,,,95.0,1.747,5.754,"resistance for the inhA gene were found in 54.5%, 40.7%, and 4.7% cases, respectively. MDR-contact (AOR 3"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,14,4.7,4.7,,,,95.0,1.747,5.754,"for the inhA gene were found in 54.5%, 40.7%, and 4.7% cases, respectively. MDR-contact (AOR 3.171 95% C"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,15,95.0,95,,,,95.0,1.747,5.754,"4.7% cases, respectively. MDR-contact (AOR 3.171 95% CI: 1.747-5.754, p-0.000) treatment failure (AOR"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,16,2.17595,2.17595,,,,95.0,1.747,5.754,"CI: 1.747-5.754, p-0.000) treatment failure (AOR 2.17595% CI: 1.703-2.777, p-0.000) and female gender (AOR"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,17,95.0,95,,,,95.0,1.747,5.754,".703-2.777, p-0.000) and female gender (AOR 1.315 95% CI: 1.117-1.548, p-0.001), were positively associ"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,18,95.0,95,,,,95.0,0.801,1.546,"nificant positive association with MDR (AOR 1.113 95% CI: 0.801-1.546, p-0.523). Old age (AOR 0.994 95%"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,19,95.0,95,,,,95.0,0.801,1.546,"95% CI: 0.801-1.546, p-0.523). Old age (AOR 0.994 95% CI: 0.990-0.999, p-0.023) and HIV seropositivity"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,20,95.0,95,,,,95.0,0.801,1.546,"0.999, p-0.023) and HIV seropositivity (AOR 0.580 95% CI: 0.369-0.911, p-0.018) were negatively associa"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,21,95.0,95,,,,95.0,1.804,3.49,"ive association with treatment failure (AOR 2.509 95% CI: 1.804-3.490, p < .001), it did not show any a"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,22,95.0,95,,,,95.0,1.804,3.49,"association with previous TB treatment (AOR 1.286 95% CI: 0.765-2.164, p-0.342) or with history of cont"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,23,95.0,95,,,,95.0,0.765,2.164,"or with history of contact with MDR-TB (AOR 1.813 95% CI: 0.591-5.560, p-0.298). However, INH mono-resi"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,24,95.0,95,,,,95.0,1.021,1.662,"e previous history of treatment for TB (AOR 1.303 95% CI: 1.021-1.662, p-0.033). It was also positively"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,25,95.0,95,,,,95.0,1.021,1.662,"33). It was also positively associated (AOR 2.094 95% CI: 1.236-3.548, p-0.006) with MDR-TB contacts. T"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,26,8.4,8.4,,,,,,,is region shows a decrease in MDR prevalence from 8.4% in 2015 to 1.3% in 2018. A similar trend is obser
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,27,1.3,1.3,,,,,,,a decrease in MDR prevalence from 8.4% in 2015 to 1.3% in 2018. A similar trend is observed for Rifampic
33062976,"Profile of HIV and multidrug-resistant tuberculosis in orphans living in orphanages in Mumbai, Maharashtra, India.",0,61.1,61.1,,,,,,,"ted children in orphanage A, boys constituted 11 (61.1%) and girls were 7 (38.9%), whereas orphanage B ha"
33062976,"Profile of HIV and multidrug-resistant tuberculosis in orphans living in orphanages in Mumbai, Maharashtra, India.",1,38.9,38.9,,,,,,,"A, boys constituted 11 (61.1%) and girls were 7 (38.9%), whereas orphanage B had all girls ( Children in"
33062976,"Profile of HIV and multidrug-resistant tuberculosis in orphans living in orphanages in Mumbai, Maharashtra, India.",2,3.5,3.5,,,,,,,"in both orphanages, with prevalence ranging from 3.5% to 5.5%."
33062976,"Profile of HIV and multidrug-resistant tuberculosis in orphans living in orphanages in Mumbai, Maharashtra, India.",3,5.5,5.5,,,,,,,"orphanages, with prevalence ranging from 3.5% to 5.5%."
32862166,High degree of fluoroquinolone resistance among extrapulmonary tuberculosis patients at a tertiary care center in North India.,0,20.4,20.4,,11.0,54.0,,,,ve to FLDs. Monoresistance of FQs was observed in 20.4% (11/54) among RR/MDR-TB isolates and 4.3% (15/348
32862166,High degree of fluoroquinolone resistance among extrapulmonary tuberculosis patients at a tertiary care center in North India.,1,4.3,4.3,,15.0,348.0,,,,ved in 20.4% (11/54) among RR/MDR-TB isolates and 4.3% (15/348) among FLD-sensitive isolates. The high d
32719234,"Trends & treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009-2014): A retrospective record-based study.",0,59.12,59.12,,,,,,,"dentified from the treatment cards, of whom 1749 (59.12%) were males. The mean (±standard deviation) age w"
32719234,"Trends & treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009-2014): A retrospective record-based study.",1,53.28,53.28,,,,,,,"ourable treatment outcomes were reported in 1371 (53.28%) patients, but they showed a declining trend duri"
32461400,Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India.,0,6.25,6.25,,,,,,,"equencing and spoligotyping, respectively. Three (6.25%), 12 (44.44%) and 12 (29.27%) MDR-TB isolates fro"
32461400,Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India.,1,44.44,44.44,,,,,,,"d spoligotyping, respectively. Three (6.25%), 12 (44.44%) and 12 (29.27%) MDR-TB isolates from western, no"
32461400,Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India.,2,29.27,29.27,,,,,,,"respectively. Three (6.25%), 12 (44.44%) and 12 (29.27%) MDR-TB isolates from western, northern and south"
32461400,Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India.,3,30.15,30.15,,,,,,,"h OFX-resistant MDR-TB cases (P <0.05). Among 35 (30.15%) phenotypically OFX-resistant isolates, 22 (62.86"
32461400,Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India.,4,62.86,62.86,,,,,,,"0.15%) phenotypically OFX-resistant isolates, 22 (62.86%) had mutations in the gyrA gene and two (5.71%) i"
32461400,Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India.,5,5.71,5.71,,,,,,,(62.86%) had mutations in the gyrA gene and two (5.71%) isolates had mutations in the gyrB gene. These r
32218585,The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.,0,23.9,23.9,,,,,,,ould reduce the annual incidence of TB in 2030 by 23.9% [95% Bayesian credible intervals [CrI] 17.6-30.8%
32218585,The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.,1,95.0,95,,,,,,,duce the annual incidence of TB in 2030 by 23.9% [95% Bayesian credible intervals [CrI] 17.6-30.8%] if
32218585,The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.,2,30.8,30.8,,,,,,,"23.9% [95% Bayesian credible intervals [CrI] 17.6-30.8%] if used to treat all TB cases, and by 2.30% [95%"
32218585,The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.,3,2.3,2.30,,,,,,,"17.6-30.8%] if used to treat all TB cases, and by 2.30% [95% CrI 1.57-3.48%] if used to treat only RR-TB."
32218585,The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.,4,95.0,95,,,,,,,".8%] if used to treat all TB cases, and by 2.30% [95% CrI 1.57-3.48%] if used to treat only RR-TB. Nota"
32218585,The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.,5,3.48,3.48,,,,,,,"to treat all TB cases, and by 2.30% [95% CrI 1.57-3.48%] if used to treat only RR-TB. Notably, with a reg"
32218585,The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.,6,95.0,95,,,,,,,"otably, with a regimen costing less than USD 359 (95% CrI 287-441), treating all diagnosed TB cases wit"
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,0,85.0,85,68.0,,,,,,". Of 378 patients enrolled (median age: 45 years; 85% males), 18% (n = 68) were rifampin-resistant. Amo"
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,1,18.0,18,68.0,9.0,89.0,,,,"ients enrolled (median age: 45 years; 85% males), 18% (n = 68) were rifampin-resistant. Among Xpert pos"
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,2,10.0,10,9.0,9.0,89.0,,,,"positives (n = 305), distributions of RR-TB were: 10% (n = 9/89) for recurrent cases who had received T"
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,3,15.0,15,9.0,9.0,59.0,,,,"ases who had received TB treatment for <2-months, 15% each for new (n = 9/59) or recurrent cases (n = 5"
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,4,36.0,36,41.0,41.0,113.0,,,,"ear positive between 2 and 4 months of treatment, 36% (n = 41/113) for treatment failures, and 40% (n ="
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,5,40.0,40,2.0,2.0,5.0,,,,"ent, 36% (n = 41/113) for treatment failures, and 40% (n = 2/5) for loss to follow-ups. Of the sputum-s"
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,6,15.0,15,51.0,51.0,338.0,,,,"oss to follow-ups. Of the sputum-smear positives, 15% (n = 51/338) were Xpert negative. Seeking care in"
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,7,95.0,95,51.0,51.0,338.0,95.0,0.87,3.9,as associated with higher risk of RR-TB (OR:1.85; 95% CI:0.87-3.9). Prevalence of RR-TB is generally hi
32192613,Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.,0,50.0,50,,,,,,,g-resistant tuberculosis (MDR-TB); with less than 50% having successful treatment outcomes. Bedaquiline
32192613,Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.,1,56.0,56,,,,,,,try. Six hundred and twenty MDR-TB patients [349 (56%) males; 554 (89%) between 18 and 50 years and 240
32192613,Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.,2,89.0,89,,,,,,,and twenty MDR-TB patients [349 (56%) males; 554 (89%) between 18 and 50 years and 240 (39%) severely m
32192613,Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.,3,39.0,39,,,,,,,males; 554 (89%) between 18 and 50 years and 240 (39%) severely malnourished] were started on BDQ conta
32192613,Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.,4,57.0,57,,,,,,,men between June 2016 and August 2017. There 354 (57%) patients had MDR-TB with additional drug resista
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,0,34.5,34.5,,,,,,,113 MDR-TB isolates. The results showed that 39 (34.5%) of these isolates were resistant to FQ and 7 (6.
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,1,6.2,6.2,,,,,,,5%) of these isolates were resistant to FQ and 7 (6.2%) were XDR by Genotype MTBDRsl V2.0. Amongst the F
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,2,38.6,38.6,,,,,,,olates most prevalent mutation was ΔWT3-D94G (17; 38.6%) and N538D (12; 85.7%). Among the AG/CP and KAN r
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,3,85.7,85.7,,,,,,,mutation was ΔWT3-D94G (17; 38.6%) and N538D (12; 85.7%). Among the AG/CP and KAN resistant isolates most
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,4,71.4,71.4,,,,,,,on mutation in the rrs region was ΔWT1-A1401G (5; 71.4%) and C-14T (2; 28.5%) in eis gene. Second line Ba
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,5,28.5,28.5,,,,,,,s region was ΔWT1-A1401G (5; 71.4%) and C-14T (2; 28.5%) in eis gene. Second line Bactec MGIT-960 detecte
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,6,35.4,35.4,,,,,,,is gene. Second line Bactec MGIT-960 detected 40 (35.4%) isolates as resistant to FQ and 6 (5.3%) as XDR
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,7,5.3,5.3,,,,,,,"ted 40 (35.4%) isolates as resistant to FQ and 6 (5.3%) as XDR isolates, whereas Genotype MTBDRsl V1.0 a"
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,8,34.5,34.5,,,,,,,", whereas Genotype MTBDRsl V1.0 also detected 39 (34.5%) as resistant to FQ but missed 2 isolates in corr"
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,9,4.4,4.4,,,,,,,"ed 2 isolates in correctly identifying as XDR (5; 4.4%). Thus, concordance of second line Bactec MGIT-96"
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,10,100.0,100,,,,,,,MGIT-960 with Genotype MTBDRsl V2.0 was similar (100%) for FQ detection but it has improvised the diagn
31742141,Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis.,0,95.0,95,,,,,,,ifferent MeSH words. Prevalence was reported with 95% confidence interval (CI). A separate analysis was
31742141,Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis.,1,3.0,3,,,,,,,"assessed by I MDR-TB prevalence in new cases were 3% (95% CI 2%-5%, I MDR-TB prevalence in previously"
31742141,Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis.,2,95.0,95,,,,,,,"ssed by I MDR-TB prevalence in new cases were 3% (95% CI 2%-5%, I MDR-TB prevalence in previously treat"
31742141,Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis.,3,2.0,2,,,,,,,"I MDR-TB prevalence in new cases were 3% (95% CI 2%-5%, I MDR-TB prevalence in previously treated pat"
31742141,Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis.,4,5.0,5,,,,,,,"MDR-TB prevalence in new cases were 3% (95% CI 2%-5%, I MDR-TB prevalence in previously treated patien"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",0,20.0,20,,,,,,,"people developed TB in 2017. India accounted for 20 % of world cases. Globally, 3.5 % of new cases and"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",1,3.5,3.5,,,,,,,"ndia accounted for 20 % of world cases. Globally, 3.5 % of new cases and 18% of previously treated cases"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",2,18.0,18,,,,,,,"of world cases. Globally, 3.5 % of new cases and 18% of previously treated cases had MDR-TB. Correspon"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",3,2.8,2.8,,,,,,,"s had MDR-TB. Corresponding figures for India are 2.8 % and 12 %. Among cases of MDR-TB in 2017, 8.5% wer"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",4,12.0,12,,,,,,,"TB. Corresponding figures for India are 2.8 % and 12 %. Among cases of MDR-TB in 2017, 8.5% were estimat"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",5,8.5,8.5,,,,,,,"re 2.8 % and 12 %. Among cases of MDR-TB in 2017, 8.5% were estimated to have XDR-TB. Drug resistant TB"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",6,41.86,41.86,,,,,,,"DR-TB patients were analyzed, which revealed 293 (41.86 %) patients of MDR-TB and 23 (45.10 %) patients of"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",7,45.1,45.10,,,,,,,revealed 293 (41.86 %) patients of MDR-TB and 23 (45.10 %) patients of XDR-TB in the age group of 15 to 25
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",0,79.2,79.2,,,,,,,of 250 patients were included in the study; 198 (79.2%) with multidrug-resistant (MDR-TB) and 52 (20.8%)
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",1,20.8,20.8,,,,,,,(79.2%) with multidrug-resistant (MDR-TB) and 52 (20.8%) with extensively drug-resistant TB (XDR-TB). Of
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",2,66.0,66,,,,,,,"extensively drug-resistant TB (XDR-TB). Of these, 66% patients were male and 46% came from poor socioec"
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",3,46.0,46,,,,,,,"TB (XDR-TB). Of these, 66% patients were male and 46% came from poor socioeconomic background. All the"
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",4,32.0,32,,,,,,,before the current diagnosis of DR-TB. While 81 (32%) took treatment from private practitioner during
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",5,58.0,58,,,,,,,"practitioner during the first episode of TB, 146 (58%) received treatment exclusively at government hea"
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",6,87.0,87,,,,,,,clusively at government health facilities. Almost 87% of DR-TB patients were previously treated with ca
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",7,35.0,35,,,,,,,CP. Irregularity of treatment was reported by 88 (35%) patients. The study explores the epidemiological
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,0,7.0,7,,,,,,,"exhibited a significant increase in positivity of 7% and 4% over ZN smear and LED-FM smear (p<0.05), r"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,1,4.0,4,,,,,,,"ed a significant increase in positivity of 7% and 4% over ZN smear and LED-FM smear (p<0.05), respecti"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,2,16.0,16,148.0,,,,,,crement in smear grade status (1+ or 2+ to 3+) of 16% over ZN smear and 20% over LED-FM smear. The sens
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,3,20.0,20,148.0,,,,,,status (1+ or 2+ to 3+) of 16% over ZN smear and 20% over LED-FM smear. The sensitivity of Mol-DST in
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,4,90.0,90,148.0,,,,,,"presumptive MDR-TB and XDR-TB cases (n = 148) was 90% for Rifampicin (95% confidence interval [CI], 78-"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,5,95.0,95,148.0,,,,,,"nd XDR-TB cases (n = 148) was 90% for Rifampicin (95% confidence interval [CI], 78-96%), 84% for Isonia"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,6,96.0,96,148.0,,,,,,"for Rifampicin (95% confidence interval [CI], 78-96%), 84% for Isoniazid (95% CI, 72-92%), 83% for Flu"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,7,84.0,84,148.0,,,,,,"ifampicin (95% confidence interval [CI], 78-96%), 84% for Isoniazid (95% CI, 72-92%), 83% for Fluoroqui"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,8,95.0,95,148.0,,,,,,"idence interval [CI], 78-96%), 84% for Isoniazid (95% CI, 72-92%), 83% for Fluoroquinolones (95% CI, 66"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,9,92.0,92,148.0,,,,,,"rval [CI], 78-96%), 84% for Isoniazid (95% CI, 72-92%), 83% for Fluoroquinolones (95% CI, 66-93%) and 7"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,10,83.0,83,148.0,,,,,,"CI], 78-96%), 84% for Isoniazid (95% CI, 72-92%), 83% for Fluoroquinolones (95% CI, 66-93%) and 75% for"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,11,95.0,95,,,,,,,"iazid (95% CI, 72-92%), 83% for Fluoroquinolones (95% CI, 66-93%) and 75% for Aminoglycosides (95% CI,"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,12,93.0,93,,,,,,,"CI, 72-92%), 83% for Fluoroquinolones (95% CI, 66-93%) and 75% for Aminoglycosides (95% CI, 35-97%), us"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,13,75.0,75,,,,,,,"%), 83% for Fluoroquinolones (95% CI, 66-93%) and 75% for Aminoglycosides (95% CI, 35-97%), using pheno"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,14,95.0,95,,,,,,,"nes (95% CI, 66-93%) and 75% for Aminoglycosides (95% CI, 35-97%), using phenotypic DST as the referenc"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,15,97.0,97,,,,,,,", 66-93%) and 75% for Aminoglycosides (95% CI, 35-97%), using phenotypic DST as the reference standard."
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,16,93.0,93,,,,,,,s the reference standard. Test specificity was 88-93% and concordance was ~89-92% (κ value 0.8-0.9). Th
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,17,92.0,92,,,,,,,st specificity was 88-93% and concordance was ~89-92% (κ value 0.8-0.9). The patient-friendly kits desc
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,0,10.12,10.12,,349.0,3447.0,,,,e inclusion criteria. Ototoxicity was observed in 10.12% [349/3447] patients within 3.8 ± 2.6 months of tr
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,1,27.01,27.01,,121.0,448.0,,,,st-SLI initiation and ototoxicity was observed in 27.01% (121/448) patients in these five studies. Sensori
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,2,25.0,25.0,,1.0,4.0,,,,"three studies (high frequency loss: capreomycin, 25.0% [1/4 patients]; amikacin, 19.7% [12/61]; kanamyci"
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,3,19.7,19.7,,12.0,61.0,,,,"oss: capreomycin, 25.0% [1/4 patients]; amikacin, 19.7% [12/61]; kanamycin, 13.3% [22/166]; streptomycin,"
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,4,13.3,13.3,,22.0,166.0,,,,"/4 patients]; amikacin, 19.7% [12/61]; kanamycin, 13.3% [22/166]; streptomycin, 11.8% [2/17]; flat loss:"
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,5,11.8,11.8,,2.0,17.0,,,,"[12/61]; kanamycin, 13.3% [22/166]; streptomycin, 11.8% [2/17]; flat loss: amikacin, 8.2% [5/61]; strepto"
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,6,8.2,8.2,,5.0,61.0,,,,"streptomycin, 11.8% [2/17]; flat loss: amikacin, 8.2% [5/61]; streptomycin, 5.9% [1/17]; kanamycin 4.8%"
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,7,5.9,5.9,,1.0,17.0,,,,"; flat loss: amikacin, 8.2% [5/61]; streptomycin, 5.9% [1/17]; kanamycin 4.8% [8/166]). Most of the pati"
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,8,4.8,4.8,,8.0,166.0,,,,"8.2% [5/61]; streptomycin, 5.9% [1/17]; kanamycin 4.8% [8/166]). Most of the patients experiencing ototo"
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,9,49.6,49.6,,120.0,242.0,,,,encing ototoxicity were managed by discontinuing (49.6% [120/242]) or replacing SLI treatment (40.8% [49/
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,10,40.8,40.8,,49.0,120.0,,,,ing (49.6% [120/242]) or replacing SLI treatment (40.8% [49/120]). The study identified high prevalence o
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,11,27.01,27.01,,,,,,,"en ototoxicity was monitored regularly using PTA (27.01%), warranting a need to develop unified guidelines"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,0,50.5,50.5,,52.0,103.0,,,,"ment outcomes. Out of 103 DRTB patients enrolled, 50.5% (52/103) patients were diagnosed with isoniazid m"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,1,67.3,67.3,,,,,,,52 isoniazid mono-resistant patients revealed:35 (67.3%) were males and 17 (32.7%) females. 27 (51.9%) pa
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,2,32.7,32.7,,,,,,,"t patients revealed:35 (67.3%) were males and 17 (32.7%) females. 27 (51.9%) patients were <30 years, 25"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,3,51.9,51.9,,34.0,52.0,,,,"35 (67.3%) were males and 17 (32.7%) females. 27 (51.9%) patients were <30 years, 25 (48.1%) being ≥30 ye"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,4,48.1,48.1,,34.0,52.0,,,,"females. 27 (51.9%) patients were <30 years, 25 (48.1%) being ≥30 years of age. All patients were negati"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,5,65.4,65.4,,34.0,52.0,,,,"f age. All patients were negative for HIV. 34/52 (65.4%) patients were declared cured, 15/52 were lost to"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,6,93.3,93.3,,14.0,15.0,,,,"tes were significantly better in females (14/15 = 93.3%), with only 1/15 LTFU, than males (20/34 = 58.8%"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,7,58.8,58.8,,20.0,34.0,,,,"93.3%), with only 1/15 LTFU, than males (20/34 = 58.8% cure, 14/34 = 41.2% LTFU), (p = 0.019). Patients"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,8,41.2,41.2,,14.0,34.0,,,,"/15 LTFU, than males (20/34 = 58.8% cure, 14/34 = 41.2% LTFU), (p = 0.019). Patients who were <30 years o"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,9,84.0,84,,21.0,25.0,,,,"age had significantly better cure rates (21/25 = 84%) with lesser LTFU's (4/25 = 16%), than those ≥30y"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,10,16.0,16,,4.0,25.0,,,,"re rates (21/25 = 84%) with lesser LTFU's (4/25 = 16%), than those ≥30years of age (13/24 = 54.2% cure,"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,11,54.2,54.2,,13.0,24.0,,,,"(4/25 = 16%), than those ≥30years of age (13/24 = 54.2% cure, 11/24 = 45.8% LTFU), (p = 0.032). Review of"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,12,45.8,45.8,,11.0,24.0,,,,"hose ≥30years of age (13/24 = 54.2% cure, 11/24 = 45.8% LTFU), (p = 0.032). Review of previous history of"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,13,78.8,78.8,,26.0,33.0,,,,"rimary isoniazid mono-resistant patients (26/33 = 78.8%), than those with previous history of being LTFU("
31114100,"A Survey of Medical Professionals in an Apex Tertiary Care Hospital to Assess Awareness, Interest, Practices, and Knowledge in Palliative Care: A Descriptive Cross-sectional Study.",0,56.0,56,,,,,,,"ledge of palliative care. Out of 186 respondents, 56% had not received any basic training in palliative"
31114100,"A Survey of Medical Professionals in an Apex Tertiary Care Hospital to Assess Awareness, Interest, Practices, and Knowledge in Palliative Care: A Descriptive Cross-sectional Study.",1,81.0,81,,,,,,,t received any basic training in palliative care. 81% wanted palliative care education to be included i
31114100,"A Survey of Medical Professionals in an Apex Tertiary Care Hospital to Assess Awareness, Interest, Practices, and Knowledge in Palliative Care: A Descriptive Cross-sectional Study.",2,77.0,77,,,,,,,most common barrier in learning palliative care. 77% respondents had no idea about home based palliati
31114100,"A Survey of Medical Professionals in an Apex Tertiary Care Hospital to Assess Awareness, Interest, Practices, and Knowledge in Palliative Care: A Descriptive Cross-sectional Study.",3,50.8,50.8,,,,,,,o idea about home based palliative care services. 50.8% patients dies in hospital in their terminal stage
31114100,"A Survey of Medical Professionals in an Apex Tertiary Care Hospital to Assess Awareness, Interest, Practices, and Knowledge in Palliative Care: A Descriptive Cross-sectional Study.",4,88.0,88,,,,,,,atients dies in hospital in their terminal stage. 88% were interested in learning safe opioid practices
31114100,"A Survey of Medical Professionals in an Apex Tertiary Care Hospital to Assess Awareness, Interest, Practices, and Knowledge in Palliative Care: A Descriptive Cross-sectional Study.",5,89.8,89.8,,,,,,,ested in learning safe opioid practices. Although 89.8% were aware of the need of palliative care in meta
31114100,"A Survey of Medical Professionals in an Apex Tertiary Care Hospital to Assess Awareness, Interest, Practices, and Knowledge in Palliative Care: A Descriptive Cross-sectional Study.",6,50.0,50,,,,,,,alliative care in metastatic cancer but less than 50% were aware of the fact that palliative care is al
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,0,70.0,70,,,,,,,Private healthcare is choice of point of care for 70% of Indians. Multidrug resistant tuberculosis (MDR
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,1,37.0,37,,,,,,,or EPTB. The major expense was due to drug costs (37%) while consultation fees were only 5%. Annual ind
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,2,5.0,5,,,,,,,rug costs (37%) while consultation fees were only 5%. Annual individual income for the cohort ranged f
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,3,2.56,2.56,,34.0,50.0,,,,"0). On average, the cost of treatment ranged from 2.56% to 180.34% of the annual family income. 34/50 (68"
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,5,68.0,68,,34.0,50.0,,,,6% to 180.34% of the annual family income. 34/50 (68%) had total costs greater than 20% of annual famil
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,6,20.0,20,,39.0,50.0,,,,income. 34/50 (68%) had total costs greater than 20% of annual family income and 39/50 (78%) had total
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,7,78.0,78,,39.0,50.0,,,,eater than 20% of annual family income and 39/50 (78%) had total costs greater than 10% of annual famil
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,8,10.0,10,,39.0,50.0,,,,come and 39/50 (78%) had total costs greater than 10% of annual family income. The number of patients w
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,9,40.0,40,,39.0,50.0,,,,income. The number of patients with total costs >40% of total family income was 22. MDR-TB in the priv
30675322,Rapid detection of multidrug resistant tuberculosis in respiratory specimens at a tertiary care centre in south coastal Karnataka using Genotype MTBDR plus assay.,0,19.53,19.53,,,,,,,"ed of MDR-TB were tested by GenoType MTBDR Fifty (19.53%) isolates were found MDR, 32 (12.50%) isolates we"
30675322,Rapid detection of multidrug resistant tuberculosis in respiratory specimens at a tertiary care centre in south coastal Karnataka using Genotype MTBDR plus assay.,1,12.5,12.50,,,,,,,"MTBDR Fifty (19.53%) isolates were found MDR, 32 (12.50%) isolates were found mono-resistant to isoniazid"
30675322,Rapid detection of multidrug resistant tuberculosis in respiratory specimens at a tertiary care centre in south coastal Karnataka using Genotype MTBDR plus assay.,2,5.86,5.86,,,,,,,es were found mono-resistant to isoniazid and 15 (5.86%) isolates were found mono-resistant to rifampicin
30675322,Rapid detection of multidrug resistant tuberculosis in respiratory specimens at a tertiary care centre in south coastal Karnataka using Genotype MTBDR plus assay.,3,4.3,4.3,,,,,,,"nd mono-resistant to rifampicin. Eleven isolates (4.3%) were found NTM. Mutation in codon S531L, S315T1"
30668857,Genetic diversity of Mycobacterium tuberculosis Central Asian Strain isolates from Nepal and comparison with neighboring countries.,0,23.3,23.3,,,,,,,"composed of 14 isolates with a clustering rate of 23.3%, suggesting ongoing transmissions. Based on MST d"
30611735,"Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of M. tuberculosis isolates from Sahariya tribe of Madhya Pradesh India.",0,12.6,12.6,,,,,,,"ug susceptibility test identified high incidence (12.6%) of isoniazid-resistant tuberculosis, while 4.85%"
30611735,"Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of M. tuberculosis isolates from Sahariya tribe of Madhya Pradesh India.",1,4.85,4.85,,,,,,,"12.6%) of isoniazid-resistant tuberculosis, while 4.85% isolates were multi drug resistant (MDR). Further"
30611735,"Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of M. tuberculosis isolates from Sahariya tribe of Madhya Pradesh India.",2,8.7,8.7,,,,,,,urther genotyping of drug target genes identified 8.7% of isoniazid-R isolates to have a mutation at kat
30611735,"Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of M. tuberculosis isolates from Sahariya tribe of Madhya Pradesh India.",3,3.8,3.8,,,,,,,"lates to have a mutation at katG codon 463, while 3.8% isolates showed mutations at two sites, katG codo"
30611735,"Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of M. tuberculosis isolates from Sahariya tribe of Madhya Pradesh India.",4,3.85,3.85,,,,,,,"In case of MDR-TB isolates, all from CAS lineage, 3.85% had mutations on katG and rpoB genes, at codon 46"
30611735,"Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of M. tuberculosis isolates from Sahariya tribe of Madhya Pradesh India.",5,0.97,0.97,,,,,,,", at codon 463 and codon 526, respectively, while 0.97% isolates were harbouring mutations at codons 315,"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",0,14.2,14.2,,7.0,100.0,,,,"B, and past TB (recurrent cases). Total 29 cases (14.2%) had recurrence (17.7/100,000 population) with si"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",1,50.0,50.0,,7.0,100.0,,,,"high fraction for alternate residence (Recurrent: 50.0%, Non-recurrent: 47.4%; p = 0.001), Multi-drug res"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",2,47.4,47.4,,7.0,100.0,,,,"rnate residence (Recurrent: 50.0%, Non-recurrent: 47.4%; p = 0.001), Multi-drug resistance (MDR) TB (Recu"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",3,13.8,13.8,,,,,,,".001), Multi-drug resistance (MDR) TB (Recurrent: 13.8%, Non-recurrent: 2.3%; p = 0.003), and sputum nega"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",4,2.3,2.3,,,,,,,"stance (MDR) TB (Recurrent: 13.8%, Non-recurrent: 2.3%; p = 0.003), and sputum negative patients (Recurr"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",5,51.7,51.7,,,,,,,"0.003), and sputum negative patients (Recurrent: 51.7%, Non-recurrent: 14.5%; p = 0.000). Non-recurrent"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",6,14.5,14.5,,,,,,,"gative patients (Recurrent: 51.7%, Non-recurrent: 14.5%; p = 0.000). Non-recurrent cases had significantl"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",7,48.3,48.3,,,,,,,"gh fraction for sputum positive cases (Recurrent: 48.3%, Non-recurrent: 72.1%; p = 0.011), and extra-pulm"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",8,72.1,72.1,,,,,,,"positive cases (Recurrent: 48.3%, Non-recurrent: 72.1%; p = 0.011), and extra-pulmonary TB (Recurrent: 0"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",9,0.0,00.0,,,,,,,"%; p = 0.011), and extra-pulmonary TB (Recurrent: 00.0%, Non-recurrent: 13.4%; p = 0.036). MFA observed a"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",10,13.4,13.4,,,,,,,"ra-pulmonary TB (Recurrent: 00.0%, Non-recurrent: 13.4%; p = 0.036). MFA observed all significant one-way"
30531028,Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.,0,11.02,11.02,,,,,,,"sly treated cases by GenoType MDR-TB was detected 11.02%, 20.03% in new and previously treated cases. Amon"
30531028,Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.,1,20.03,20.03,,,,,,,"ted cases by GenoType MDR-TB was detected 11.02%, 20.03% in new and previously treated cases. Among MDR-TB"
30531028,Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.,2,71.43,71.43,,,,,,,"s the most common mutation detected in rpoB gene; 71.43% in new, and 72.17% in previously treated cases. S"
30531028,Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.,3,72.17,72.17,,,,,,,"utation detected in rpoB gene; 71.43% in new, and 72.17% in previously treated cases. S315T1 was the most"
30531028,Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.,4,100.0,100,,,,,,,was the most common mutation noted in katG gene; 100% in new and 81.74% in previously treated. While in
30531028,Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.,5,81.74,81.74,,,,,,,"mmon mutation noted in katG gene; 100% in new and 81.74% in previously treated. While in hA gene, it was C"
30531028,Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.,6,7.8,7.8,,,,,,,"reviously treated. While in hA gene, it was C15T (7.8%) among previously treated cases. MDR-TB has high"
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,0,2.1,2.1,,,,,,,proportion of multidrug-resistant TB (MDR-TB) is 2.1% (in new TB cases) and 15% (in previously treated
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,1,15.0,15,,,,,,,sistant TB (MDR-TB) is 2.1% (in new TB cases) and 15% (in previously treated cases). Programmatic manag
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,2,64.81,64.81,,,,,,,nalysis. Of total 108 patients majority patients (64.81%) were in young (20-39 years) with m:f: 2:1. All M
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,3,69.44,69.44,,,,,,,"2:1. All MDR-TB patients were retreated cases and 69.44% were ""undernutrition category"". Culture conversio"
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,4,86.91,86.91,,,,,,,"rnutrition category"". Culture conversion rate was 86.91% at 4 months of treatment. Cure rate was 50.93% wh"
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,5,50.93,50.93,,,,,,,as 86.91% at 4 months of treatment. Cure rate was 50.93% while defaulter rate and died rate was same (17.5
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,6,17.59,17.59,,,,,,,.93% while defaulter rate and died rate was same (17.59%). Failure rate was 18.51%. Weight improvement was
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,7,18.51,18.51,,,,,,,and died rate was same (17.59%). Failure rate was 18.51%. Weight improvement was significantly associated
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,8,32.71,32.71,,,,,,,sociated with cure rate. The incidence of ADR was 32.71%. Most frequent ADRs were related to gastrointesti
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,9,34.42,34.42,,,,,,,"ent ADRs were related to gastrointestinal system (34.42%), ototoxicity (13.11%), and central nervous syste"
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,10,13.11,13.11,,,,,,,"to gastrointestinal system (34.42%), ototoxicity (13.11%), and central nervous system (8.1%). Aminoglycosi"
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,11,8.1,8.1,,,,,,,"ototoxicity (13.11%), and central nervous system (8.1%). Aminoglycosides, cycloserine, and ethambutol we"
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,12,77.04,77.04,,,,,,,"utol were discontinued due to ADR. Majority ADRs (77.04%) were ""possible"" category by causality assessment"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,0,3.0,3,,,,,,,-TB). While prevalence of MDR-TB is known to be 2-3% among new TB patients and 12-17% in previously tr
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,1,17.0,17,,,,,,,"is known to be 2-3% among new TB patients and 12-17% in previously treated patients, programmatic info"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,2,91.5,91.5,,,,,,,"d between July 2011 and Sep 2013. Of these, 1602 (91.5%) MDR-TB patients were included in the study. A to"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,3,1.8,1.8,,,,,,,"per MDR-TB patient. Of these, after excluding 87 (1.8%) contacts with past history of diagnosis and/or t"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,4,98.2,98.2,,,,,,,"story of diagnosis and/or treatment for TB, 4771 (98.2%) contacts were screened for current signs and sym"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,5,45.0,45,,,,,,,"ve of TB. Their mean age was 28.5 years and 2151 (45%) were females. Of the 4771 contacts screened, 793"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,6,16.6,16.6,,,,,,,"were females. Of the 4771 contacts screened, 793 (16.6%) had at least one of the symptoms suggestive of T"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,7,98.5,98.5,,,,,,,one of the symptoms suggestive of TB of whom 781 (98.5%) had two sputum specimen transported and tested o
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,8,4.4,4.4,,,,,,,"TB. Among 781 symptomatic contacts examined, 34 (4.4%) were bacteriologically confirmed with TB and 15"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,9,44.0,44,,,,,,,"were bacteriologically confirmed with TB and 15 (44%) also had Rif resistance (RR). High extent of TB,"
29933862,Cost effectiveness of decentralised care model for managing MDR-TB in India.,0,23.0,23,,,,,,,ised care the cost difference would range between 23% and 94% for the country. Our study provides evide
29933862,Cost effectiveness of decentralised care model for managing MDR-TB in India.,1,94.0,94,,,,,,,e the cost difference would range between 23% and 94% for the country. Our study provides evidence of c
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",0,62.0,62,,,,,,,. 50 pediatricians participated in the study with 62% having an attachment to the teaching institution.
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",1,50.0,50,,,,,,,attachment to the teaching institution. More than 50% identified all the symptoms of TB. 64% were sendi
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",2,64.0,64,,,,,,,"More than 50% identified all the symptoms of TB. 64% were sending chest X-ray, Mantoux test and gastri"
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",3,22.0,22,,,,,,,nduced sputum examination for AFB to diagnose TB. 22% were not stressing for AFB examination. Still 16%
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",4,16.0,16,,,,,,,22% were not stressing for AFB examination. Still 16% told serological tests as one of the diagnostic m
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",5,52.0,52,,,,,,,ological tests as one of the diagnostic modality. 52% were not aware about the diagnosis of latent TB.
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",6,16.0,16,,,,,,,re not aware about the diagnosis of latent TB. In 16% of their cases ATT was on a trial basis. Only 52%
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",7,52.0,52,,,,,,,16% of their cases ATT was on a trial basis. Only 52% of the clinicians are adhering to updated nationa
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",8,30.0,30,,,,,,,adhering to updated national (RNTCP) guidelines. 30% felt still there are drawbacks in the current RNT
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",9,72.0,72,,,,,,,re are drawbacks in the current RNTCP guidelines. 72% knew the correct definition of MDR tuberculosis.
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",10,36.0,36,,,,,,,correct definition of MDR tuberculosis. But only 36% of them knew the diagnostic method (gene expert/C
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,0,10.0,10,,,,,,,g countries. Skeletal tuberculosis accounts up to 10% of all extra pulmonary tuberculosis. World Health
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,1,53.2,53.2,,,,,,,during the period of 2006-2013 (96 months). 478 (53.2%) patients were treated for tubercular spondylitis
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,2,46.8,46.8,,,,,,,were treated for tubercular spondylitis and 420 (46.8%) for extra-spinal skeletal tuberculosis. Ninety t
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,3,10.2,10.2,,,,,,,pinal skeletal tuberculosis. Ninety two patients (10.2%) had documented resistance to the anti-tubercular
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,4,4.7,4.7,,,,,,,"There were 42 mono resistant tuberculosis cases (4.7%), 13 poly resistant cases (1.4%), 33 multi-drug r"
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,5,1.4,1.4,,,,,,,"berculosis cases (4.7%), 13 poly resistant cases (1.4%), 33 multi-drug resistant cases (MDR TB) (3.7%) a"
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,6,3.7,3.7,,,,,,,"s (1.4%), 33 multi-drug resistant cases (MDR TB) (3.7%) and 4 (0.4%) extremely drug resistant tuberculos"
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,7,0.4,0.4,,,,,,,multi-drug resistant cases (MDR TB) (3.7%) and 4 (0.4%) extremely drug resistant tuberculosis cases (XDR
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,8,66.0,66,,,,,,,cols. Surgery was performed when indicated in 59 (66%) cases. 85% completed their course of treatment a
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,9,85.0,85,,,,,,,y was performed when indicated in 59 (66%) cases. 85% completed their course of treatment and were succ
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,10,3.7,3.7,,,,,,,resistant tuberculosis patients in our centre was 3.7% and that of Extremely drug resistant tuberculosis
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,11,0.4,0.4,,,,,,,f Extremely drug resistant tuberculosis cases was 0.4%. A Multi-disciplinary approach with drug suscepti
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,0,11.8,11.8,,,,,,,"s in katG inclusive of codon 315. In total, 1821 (11.8%) of 15438 INH-resistant strains had detectable mu"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,1,71.0,71.0,,,,,,,8 INH-resistant strains had detectable mutations: 71.0% in katG315 and 29.0% in the inhA promoter region.
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,2,29.0,29.0,,,,,,,ns had detectable mutations: 71.0% in katG315 and 29.0% in the inhA promoter region. The prevalence of IH
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,3,89.1,89.1,,,,,,,"region. The prevalence of IHN monoresistance was 89.1% in the economically-active age group, 0.4% in the"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,4,0.4,0.4,,,,,,,"e was 89.1% in the economically-active age group, 0.4% in the paediatric age group and 10.5% in those ag"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,5,10.5,10.5,,,,,,,"e age group, 0.4% in the paediatric age group and 10.5% in those aged >60years; the rate in males and fem"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,6,12.0,12.0,,,,95.0,59.3,75.4,"aged >60years; the rate in males and females was 12.0% and 10.8%, respectively. Meta-analysis derived a"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,7,10.8,10.8,,,,95.0,59.3,75.4,"ears; the rate in males and females was 12.0% and 10.8%, respectively. Meta-analysis derived a pooled kat"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,8,67.3,67.3,,,,95.0,59.3,75.4,"ved a pooled katGS315T resistant TB prevalence of 67.3% (95% CI 59.3-75.4%) with Q=732.19, I INH resistan"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,9,95.0,95,,,,95.0,59.3,75.4,"ooled katGS315T resistant TB prevalence of 67.3% (95% CI 59.3-75.4%) with Q=732.19, I INH resistance wa"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,10,75.4,75.4,,,,95.0,59.3,75.4,"15T resistant TB prevalence of 67.3% (95% CI 59.3-75.4%) with Q=732.19, I INH resistance was spread widel"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",0,9.6,9.6,,,,,,,"T. The prevalence of DR-TB was 110 of 1145 cases (9.6%), which showed an increase, compared with 5.6% pr"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",1,5.6,5.6,,,,,,,"s (9.6%), which showed an increase, compared with 5.6% pre-2010 and 7% in 2010-2013 (P = 0.014408). Twen"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",2,7.0,7,,,,,,,"owed an increase, compared with 5.6% pre-2010 and 7% in 2010-2013 (P = 0.014408). Twenty-two children"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",3,20.0,20,,,,,,,in 2010-2013 (P = 0.014408). Twenty-two children (20%) had pulmonary-TB and 88 (80%) had extra-pulmonar
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",4,80.0,80,,,,,,,wenty-two children (20%) had pulmonary-TB and 88 (80%) had extra-pulmonary-TB with disseminated-TB bein
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",5,28.18,28.18,,,,,,,eing the most common presentation in 31 children (28.18%). Ninety-six children (87.3%) were bacteriologica
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",6,87.3,87.3,,,,,,,"ion in 31 children (28.18%). Ninety-six children (87.3%) were bacteriologically confirmed TB cases, and 1"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",7,12.7,12.7,,,,,,,"ere bacteriologically confirmed TB cases, and 14 (12.7%) were clinically diagnosed-TB and treated as per"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",8,7.2,7.2,,,,,,,"d-TB and treated as per contact DST. Eight cases (7.2%) were monoresistant, 7 (6.3%) polyresistant, MDR-"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",9,6.3,6.3,,,,,,,"ct DST. Eight cases (7.2%) were monoresistant, 7 (6.3%) polyresistant, MDR-TB seen in 28 patients (25.45"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",10,25.45,25.45,,,,,,,"(6.3%) polyresistant, MDR-TB seen in 28 patients (25.45%), 32 (29.09%) had pre-XDR-TB, 9 (8.18%) had XDR-T"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",11,29.09,29.09,,,,,,,"sistant, MDR-TB seen in 28 patients (25.45%), 32 (29.09%) had pre-XDR-TB, 9 (8.18%) had XDR-TB and 12 (10."
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",12,8.18,8.18,,,,,,,"patients (25.45%), 32 (29.09%) had pre-XDR-TB, 9 (8.18%) had XDR-TB and 12 (10.9%) were rifampicin resist"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",13,10.9,10.9,,,,,,,"09%) had pre-XDR-TB, 9 (8.18%) had XDR-TB and 12 (10.9%) were rifampicin resistant. Ethionamide resistanc"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",14,26.1,26.1,,,,,,,resistant. Ethionamide resistance increased from 26.1% pre-2013 to 60.8% post-2013 (P = 0.014408) and of
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",15,60.8,60.8,,,,,,,amide resistance increased from 26.1% pre-2013 to 60.8% post-2013 (P = 0.014408) and ofloxacin resistance
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",16,30.4,30.4,,,,,,,"(P = 0.014408) and ofloxacin resistance rose from 30.4% pre-2010, to 47.6% in 2010-2013 and 56.9% post-20"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",17,47.6,47.6,,,,,,,"ofloxacin resistance rose from 30.4% pre-2010, to 47.6% in 2010-2013 and 56.9% post-2013 (P = 0.080863)."
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",18,56.9,56.9,,,,,,,"se from 30.4% pre-2010, to 47.6% in 2010-2013 and 56.9% post-2013 (P = 0.080863). Moxifloxacin resistance"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",19,8.7,8.7,,,,,,,"Moxifloxacin resistance showed an acute rise from 8.7% pre-2010, to 46% in 2010-2013 and 57% post-2013 ("
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",20,46.0,46,,,,,,,"tance showed an acute rise from 8.7% pre-2010, to 46% in 2010-2013 and 57% post-2013 (P = 0.000275). Th"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",21,57.0,57,,,,,,,"rise from 8.7% pre-2010, to 46% in 2010-2013 and 57% post-2013 (P = 0.000275). Thirty-three patients ("
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",22,30.0,30,,,,,,,"post-2013 (P = 0.000275). Thirty-three patients (30%) had completed their treatment, 21 (19.09%) were"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",23,19.09,19.09,,,,,,,"patients (30%) had completed their treatment, 21 (19.09%) were lost to follow-up and 56 (50.09%) patients"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",24,50.09,50.09,,,,,,,"tment, 21 (19.09%) were lost to follow-up and 56 (50.09%) patients are still on treatment. DR-TB is increa"
29460737,"Use of Verbal Autopsy to Determine Underlying Cause of Death during Treatment of Multidrug-Resistant Tuberculosis, India.",0,50.0,50,,,,,,,"with multidrug-resistant tuberculosis (MDR TB), <50% complete treatment. Most treatment failures for p"
29460737,"Use of Verbal Autopsy to Determine Underlying Cause of Death during Treatment of Multidrug-Resistant Tuberculosis, India.",1,66.0,66,,47.0,71.0,,,,"s to ascertain the underlying cause of death. For 66% of patient deaths (47/71), TB was the underlying"
28887289,Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.,0,8.0,8.0,,,,,,,"ects, RIF resistance was observed in 70 patients (8.0%), among which pre-existing FQ resistance was dete"
28887289,Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.,1,32.0,32,,,,,,,"which pre-existing FQ resistance was detected in 32%. Moreover, 88% of isolates exhibited a similar DS"
28887289,Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.,2,88.0,88,,,,,,,"ting FQ resistance was detected in 32%. Moreover, 88% of isolates exhibited a similar DST pattern for a"
28887289,Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.,3,32.0,32,,,,,,,OFX and LVX. A huge proportion of MDR-TB strains (32%) exhibiting OFX resistance prior to treatment wit
